G H Lyman

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. pmc Use of re-randomized data in meta-analysis
    Iztok Hozo
    Department of Mathematics, Indiana University Northwest, Gary, IN, USA
    BMC Med Res Methodol 5:17. 2005
  2. ncbi request reprint Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Cancer 106:223-33. 2006
  3. ncbi request reprint A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester School of Medicine, Strong Memorial Hospital, Rochester, NY 14642 0001, USA
    Breast Cancer Res Treat 85:143-50. 2004
  4. ncbi request reprint The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia
    G H Lyman
    Department of Medicine, James P Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester, Rochester, NY 14642, USA
    Crit Rev Oncol Hematol 50:129-46. 2004
  5. ncbi request reprint Granulocyte colony-stimulating factors: finding the right indication
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Curr Opin Oncol 19:299-307. 2007
  6. ncbi request reprint The economic burden of anemia in cancer patients receiving chemotherapy
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Value Health 8:149-56. 2005
  7. pmc The strengths and limitations of meta-analyses based on aggregate data
    Gary H Lyman
    Department of Medicine, University of Rochester, Medical Center, Rochester, New York 14642, USA
    BMC Med Res Methodol 5:14. 2005
  8. ncbi request reprint Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Natl Compr Canc Netw 5:217-28. 2007
  9. ncbi request reprint Risk models for predicting chemotherapy-induced neutropenia
    Gary H Lyman
    Health Services and Outcomes Research Program, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Oncologist 10:427-37. 2005
  10. ncbi request reprint Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies
    Gary H Lyman
    Department of Medicine, James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Cancer 109:1011-8. 2007

Detail Information

Publications76

  1. pmc Use of re-randomized data in meta-analysis
    Iztok Hozo
    Department of Mathematics, Indiana University Northwest, Gary, IN, USA
    BMC Med Res Methodol 5:17. 2005
    ..The probability of an event is not always the same when a patient is re-randomized; there is probably a non-zero covariance coming from observations on the same patient. This is of particular importance to the meta-analysts...
  2. ncbi request reprint Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Cancer 106:223-33. 2006
    ..To address this, a systematic review of studies was conducted that answered the following question: Is there a clinical benefit associated with early erythropoietic intervention (hemoglobin > or = 10 g/dL) for chemotherapy-induced anemia?..
  3. ncbi request reprint A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester School of Medicine, Strong Memorial Hospital, Rochester, NY 14642 0001, USA
    Breast Cancer Res Treat 85:143-50. 2004
    ..To evaluate whether the high complete response (CR) rates for the combination of doxorubicin and paclitaxel in metastatic breast cancer observed in two European studies could be replicated in a multi-institutional cooperative group trial...
  4. ncbi request reprint The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia
    G H Lyman
    Department of Medicine, James P Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester, Rochester, NY 14642, USA
    Crit Rev Oncol Hematol 50:129-46. 2004
    ..Recent studies have demonstrated the potential value of targeting the CSFs toward patients at greatest risk based on accurate and valid predictive models...
  5. ncbi request reprint Granulocyte colony-stimulating factors: finding the right indication
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Curr Opin Oncol 19:299-307. 2007
    ..Recommendations for the use of recombinant myeloid growth factors to reduce the risk of neutropenic complications and sustain dose intensity continue to evolve...
  6. ncbi request reprint The economic burden of anemia in cancer patients receiving chemotherapy
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Value Health 8:149-56. 2005
    ..Anemia is one of the most common hematologic complications of cancer and cytotoxic treatment. The economic burden associated with anemia in patients with malignancy has not yet been extensively studied...
  7. pmc The strengths and limitations of meta-analyses based on aggregate data
    Gary H Lyman
    Department of Medicine, University of Rochester, Medical Center, Rochester, New York 14642, USA
    BMC Med Res Methodol 5:14. 2005
    ..Few would disagree that meta-analyses based on individual patient data (IPD) offer several advantages and represent the standard to which all other systematic reviews should be compared...
  8. ncbi request reprint Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Natl Compr Canc Netw 5:217-28. 2007
    ..Presentation clarity also favors National Comprehensive Cancer Network guidelines, with recommendations generally presented as both text and algorithmic diagram...
  9. ncbi request reprint Risk models for predicting chemotherapy-induced neutropenia
    Gary H Lyman
    Health Services and Outcomes Research Program, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Oncologist 10:427-37. 2005
    ..To overcome the limitations of previous studies, efforts are under way to develop and validate risk models based on large prospective studies in representative populations of patients receiving systemic chemotherapy...
  10. ncbi request reprint Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies
    Gary H Lyman
    Department of Medicine, James P Wilmot Cancer Center, University of Rochester, Rochester, New York 14642, USA
    Cancer 109:1011-8. 2007
    ..The predictive accuracy for treatment efficacy also underwent validation in 651 patients randomized on NSABP B-20 and 645 patients on NSABP B-14...
  11. ncbi request reprint Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
    J Natl Compr Canc Netw 3:557-71. 2005
    ..The clinical, economic, and quality of life data in support of these recommendations are reviewed, and important areas of ongoing research are highlighted...
  12. ncbi request reprint The challenge of systematic reviews of diagnostic and staging studies in cancer
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Cancer Treat Rev 31:628-39. 2005
    ..However, controversy remains as to which outcomes to measure and when long term outcomes based on large and costly randomized trials are required...
  13. ncbi request reprint Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Clin Breast Cancer 7:372-9. 2006
    ..The analysis reported here reviews test performance characteristics of reported gene expression signatures in women with breast cancer...
  14. ncbi request reprint Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia
    Gary H Lyman
    Health Services and Outcomes Research, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA
    Oncology (Williston Park) 20:16-20. 2006
    ..Weighing the clinical evidence together with other clinical and economic considerations should provide greater insight into the benefits of treating mild anemia in patients treated with chemotherapy...
  15. ncbi request reprint Risks and consequences of chemotherapy-induced neutropenia
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Clin Cornerstone 8:S12-8. 2006
    ..Appropriate use of myeloid growth factors is associated with reduced neutropenic complications, improved patient quality of life, and potentially improved disease control and long-term survival...
  16. ncbi request reprint Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704 Rochester, NY 14642, USA
    Leuk Lymphoma 44:2069-76. 2003
    ..13, 95% CI: 1.20-3.76). Such a model may permit the identification of patients at greatest risk of febrile neutropenia and, therefore, candidates for the selective prophylactic use of the hematopoietic growth factors...
  17. ncbi request reprint Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
    J Clin Oncol 22:4302-11. 2004
    ..To assess the incidence of and risk factors for reduced relative dose-intensity (RDI) in patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma (NHL)...
  18. ncbi request reprint Filgrastim in patients with neutropenia: potential effects on quality of life
    Gary H Lyman
    Health Services and Outcomes Research Program, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Drugs 62:65-78. 2002
    ..Additional prospective controlled trials that contain quality-of-life issues as endpoints are needed...
  19. ncbi request reprint Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, Strong Memorial Hospital, Rochester, New York 14642, USA
    Expert Opin Biol Ther 5:1635-46. 2005
    ..Ongoing clinical trials continue to explore further potential uses for pegfilgrastim...
  20. ncbi request reprint Cost effectiveness of myeloid growth factors in cancer chemotherapy
    Gary H Lyman
    Department of Medicine, University of Rochester and the James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    Curr Hematol Rep 2:471-9. 2003
    ..Continuing clinical and economic evaluation, along with an updating of clinical practice guidelines because of rapid technologic and clinical advances, is encouraged...
  21. ncbi request reprint Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma
    Gary H Lyman
    Department of Medicine, University of Rochester School of Medicine and Dentistry and the James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA
    Cancer 98:2402-9. 2003
    ..Hospitalization for chemotherapy-induced febrile neutropenia is associated with substantial cost and may negatively impact clinical outcome due to associated dose attenuation...
  22. ncbi request reprint Evidence-based use of colony-stimulating factors in elderly cancer patients
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, NY 14642, USA
    Cancer Control 10:487-99. 2003
    ..Hematopoietic growth factors have been shown to reduce the severity and duration of febrile neutropenia (FN) and to sustain chemotherapy dose intensity...
  23. ncbi request reprint Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
    J Clin Oncol 21:4524-31. 2003
    ..This retrospective study was undertaken to assess practice patterns in adjuvant chemotherapy for early-stage breast cancer (ESBC) and to define the incidence and predictive factors of reduced relative dose-intensity (RDI)...
  24. ncbi request reprint Risk assessment in oncology clinical practice. From risk factors to risk models
    Gary H Lyman
    Health Services and Outcomes Research, James P Wilmot Cancer Center, University of Rochester, School of Medicine and Dentistry, Rochester, New York, USA
    Oncology (Williston Park) 17:8-13. 2003
    ..Additional prospective research is needed to develop more accurate and valid risk models and to evaluate the efficacy and cost-effectiveness of model-targeted use of CSF in high-risk patients...
  25. ncbi request reprint Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy
    Michelle Shayne
    Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
    Cancer 110:1611-20. 2007
    ..This prospective study was undertaken to evaluate patient and treatment characteristics that contribute to hematologic toxicity in older cancer patients...
  26. ncbi request reprint Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens
    Jennifer J Griggs
    University of Rochester, Rochester, NY, USA
    J Clin Oncol 25:2522-7. 2007
    ..Breast cancer outcomes are worse among black women and women of lower socioeconomic status. The purpose of this study was to investigate racial and social differences in selection of breast cancer adjuvant chemotherapy regimens...
  27. ncbi request reprint Prophylactic colony-stimulating factors in children receiving myelosuppressive chemotherapy: a meta-analysis of randomized controlled trials
    Brenda Wittman
    Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    Cancer Treat Rev 32:289-303. 2006
    ..A systematic review of the literature and meta-analysis were conducted to definitively assess the impact of prophylactic CSFs on the risk of febrile neutropenia (FN) in pediatric oncology patients...
  28. ncbi request reprint Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
    Nicole M Kuderer
    James P Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester, New York 14642, USA
    Cancer 106:2258-66. 2006
    ..The study was undertaken to better define mortality, length of stay (LOS), cost, and risk factors associated with mortality and prolonged hospitalization in cancer patients with FN...
  29. ncbi request reprint Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective
    Leon E Cosler
    Albany College of Pharmacy, Albany, New York, USA
    Pharmacoeconomics 25:343-51. 2007
    ..This analysis presents the potential cost implications of G-CSF treatment for established neutropenia among hospitalised patients...
  30. ncbi request reprint American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    J Clin Oncol 23:7703-20. 2005
    ..To develop a guideline for the use of sentinel node biopsy (SNB) in early stage breast cancer...
  31. ncbi request reprint Balancing the benefits and costs of colony-stimulating factors: a current perspective
    Gary H Lyman
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Ave, Box 704, Rochester, NY 14642, USA
    Semin Oncol 30:10-7. 2003
    ..Preliminary results suggest that the targeted application of CSF support based on a risk model may improve the associated cost savings...
  32. doi request reprint Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States
    Gary H Lyman
    Division of Medical Oncology, Department of Medicine, Duke University School of Medicine and the Duke Comprehensive Cancer Center, Durham, North Carolina, USA
    Clin Ther 31:1092-104. 2009
    ..Prophylaxis with granulocyte colony-stimulating factor reduces the risk for febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy...
  33. ncbi request reprint Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, New York, USA
    Cancer 104:2822-9. 2005
    ..The incidence of venous thromboembolism (VTE) is increased in cancer, but little information is available about risk factors in cancer patients on chemotherapy...
  34. ncbi request reprint Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy
    Michelle Shayne
    James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Breast Cancer Res Treat 100:255-62. 2006
    ..This retrospective study was undertaken to define risk factors for reductions in dose intensity of adjuvant chemotherapy in women with early stage breast cancer (ESBC)...
  35. pmc Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action
    Alok A Khorana
    James P Wilmot Cancer Center, and Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 27:4919-26. 2009
    ..Venous thromboembolism (VTE) is an increasingly frequent complication of cancer and its treatments, and is associated with worsened mortality and morbidity in patients with cancer...
  36. ncbi request reprint Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, New York 14642, USA
    Cancer 110:2339-46. 2007
    ..In the current study, the frequency, risk factors, and trends associated with VTE were examined among hospitalized cancer patients...
  37. pmc Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer
    Alok A Khorana
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, New York, USA
    Arch Intern Med 168:2377-81. 2008
    ..Anemia is frequent in patients with cancer, but there are concerns regarding treatment with erythropoiesis-stimulating agents. Blood transfusions are commonly used as an alternative, but with little data regarding outcomes...
  38. pmc Development and validation of a predictive model for chemotherapy-associated thrombosis
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, NY, USA
    Blood 111:4902-7. 2008
    ..5 months (C-statistic = 0.7 for both cohorts). This model can identify patients with a nearly 7% short-term risk of symptomatic VTE and may be used to select cancer outpatients for studies of thromboprophylaxis...
  39. ncbi request reprint Chemotherapy dose intensity and quality cancer care
    Gary H Lyman
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Oncology (Williston Park) 20:16-25. 2006
    ..The delivery of optimal chemotherapy dose intensity in patients with potentially curable malignancies should be considered a major quality indicator in cancer patient care...
  40. ncbi request reprint Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review
    Nicole M Kuderer
    University of Rochester School of Medicine and Dentistry, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Clin Oncol 25:3158-67. 2007
    ..Several RCTs have been published recently that investigate the impact of G-CSF on mortality and relative dose-intensity (RDI)...
  41. ncbi request reprint The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients
    Neil Blumberg
    University of Rochester Medical Center, Rochester, New York 14642, USA
    Transfusion 47:573-81. 2007
    ..In clinical trials and meta-analyses investigating leukoreduced blood transfusions to reduce postoperative infections, the intention-to-treat principle and the scientific method have been variably applied...
  42. ncbi request reprint Thromboembolism in hospitalized neutropenic cancer patients
    Alok A Khorana
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 24:484-90. 2006
    ..We investigated venous and arterial thromboembolism and associated outcomes in hospitalized cancer patients actively receiving therapy, as identified by neutropenia...
  43. ncbi request reprint Undertreatment of obese women receiving breast cancer chemotherapy
    Jennifer J Griggs
    Department of Medicine, University of Rochester, Rochester, NY 14642, USA
    Arch Intern Med 165:1267-73. 2005
    ..The objective of this study was to investigate treatment patterns in overweight and obese women undergoing breast cancer adjuvant chemotherapy...
  44. ncbi request reprint Ductal carcinoma in situ: a review of recent advances
    Ping Tang
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Curr Opin Obstet Gynecol 19:63-7. 2007
    ..This review summarizes recent findings on ductal carcinoma in situ of the breast and their impact on prognosis and management of the disease...
  45. ncbi request reprint Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients
    Gary H Lyman
    Health Services and Outcomes Research Progam, James P Wilmot Cancer Center, University of Rochester, Rochester, NY, USA
    Curr Opin Hematol 9:207-14. 2002
    ..Continuing clinical and economic evaluation along with an updating of clinical practice guidelines especially related to elderly patients is recommended because of rapid technologic and clinical advances...
  46. doi request reprint Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy
    Adi Eldar-Lissai
    Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Value Health 11:172-9. 2008
    ....
  47. ncbi request reprint Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis
    Theodore Kim
    Department of Medicine, Tufts New England Medical Center, Boston, Massachusetts, USA
    Cancer 106:4-16. 2006
    ..Lymphatic mapping with sentinel lymph node biopsy has the potential for reducing the morbidity associated with breast carcinoma staging. It has become a widely used technology despite limited data from controlled clinical trials...
  48. ncbi request reprint Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy
    Jennifer J Griggs
    Department of Medicine, University of Rochester, Rochester, NY, USA
    J Clin Oncol 25:277-84. 2007
    ..The purpose of this study was to investigate the relationship between socioeconomic status (SES) and the use of intentionally reduced doses of chemotherapy in the adjuvant treatment of breast cancer...
  49. doi request reprint Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy
    Michelle Shayne
    Department of Medicine, University of Rochester and the James P Wilmot Cancer Center, Rochester, NY, USA
    Cancer 115:5319-28. 2009
    ..This prospective study evaluated patient and treatment characteristics that contributed to hematologic toxicity in older breast cancer patients treated with curative intent in the community setting...
  50. ncbi request reprint Agents under investigation for the treatment and prevention of neutropenia
    Alissa Huston
    University of Rochester, James P Wilmot Cancer Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
    Expert Opin Investig Drugs 16:1831-40. 2007
    ....
  51. pmc Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors
    Ralph Madeb
    Department of Urology, University of Rochester School of Medicine, Rochester, New York, USA
    Cancer 115:2660-70. 2009
    ..The authors sought to determine whether US urologists have adopted this practice, and its potential effect on costs of bladder cancer (BC) care...
  52. ncbi request reprint Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials
    J T Horan
    Department of Pediatrics, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    Bone Marrow Transplant 32:293-8. 2003
    ..07 for the studies enrolling a smaller proportion. This finding substantiates results from previously published studies that have demonstrated a survival advantage with PBSCT limited to patients with advanced disease...
  53. ncbi request reprint Length of stay and mortality associated with febrile neutropenia among children with cancer
    Swati K Basu
    University of Rochester Medical Center, NY 14642, USA
    J Clin Oncol 23:7958-66. 2005
    ..The aim of this study was to evaluate risk factors for longer length of stay (los) and mortality among hospitalized children with cancer who have febrile neutropenia...
  54. ncbi request reprint The colony-stimulating factors: use to prevent and treat neutropenia and its complications
    Rami S Komrokji
    University of Rochester School of Medicine and Dentistry, Department of Medicine and the James P Wilmot Cancer Center, Rochester, New York 14642, USA
    Expert Opin Biol Ther 4:1897-910. 2004
    ..Finally, clinical efficacy data, as well as the economic impact of the CSFs, are discussed...
  55. ncbi request reprint A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications
    Nicole M Kuderer
    James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
    Cancer 110:1149-61. 2007
    ....
  56. pmc Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer
    Gary H Lyman
    Department of Medicine, Duke University School of Medicine and the Duke Comprehensive Cancer Center, Durham, North Carolina 27710, USA
    Cancer 115:5637-50. 2009
    ..Widespread dissemination and application of these guidelines are encouraged to improve the appropriate use of these agents and to improve clinical outcomes in medical cancer patients at risk for VTE and its complications...
  57. ncbi request reprint Optimal cancer care across the spectrum of life and disease
    Gary H Lyman
    Department of Medicine, Duke University, 2424 Erwin Rd, Ste 602, Durham, NC 27710, USA
    Am J Manag Care 14:262-4. 2008
  58. ncbi request reprint American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
    Gary H Lyman
    Duke University Medical Center, University of Rochester Medical Center, Rochester, USA
    J Clin Oncol 25:5490-505. 2007
    ..To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer...
  59. pmc Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy
    Gregory C Connolly
    James P Wilmot Cancer Center, Department of Medicine, University of Rochester, Rochester, NY, USA
    Thromb Res 126:113-8. 2010
    ..Leukocytosis has been associated with thrombosis and mortality in cancer patients. We explored the association of leukocytosis with venous thromboembolism (VTE) and early mortality in cancer patients initiating chemotherapy...
  60. ncbi request reprint Venous thromboembolism in patients with diffuse large B-cell lymphoma
    Rami S Komrokji
    Department of Medicine, University of Cincinnati and Cincinnati Veterans Administration Medical Center, Cincinnati, OH 45267 0501, USA
    Leuk Lymphoma 47:1029-33. 2006
    ..2 years (95% CI 1.8 - 8.6) for those without VTE (P = 0.038). We conclude that VTE is a frequent complication of DLBCL that occurs particularly at diagnosis and during initial therapy, and it is associated with a worse prognosis...
  61. ncbi request reprint Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis
    Gary H Lyman
    Center for Health Outcomes and PharmacoEconomic Research, Albany Medical College, State University of New York, Albany, NY, USA
    Am J Med 112:406-11. 2002
    ..We performed a meta-analysis to define better the magnitude of this effect and to assess the generalizability of the results among different diseases and types of treatment...
  62. ncbi request reprint 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline
    Thomas J Smith
    American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, Alexandria, VA 22314, USA
    J Clin Oncol 24:3187-205. 2006
    ..Guided by the 1996 ASCO clinical outcomes criteria, the Update Committee formulated recommendations based on improvements in survival, quality of life, toxicity reduction and cost-effectiveness...
  63. ncbi request reprint Myeloid growth factors clinical practice guidelines in oncology
    Jeffrey Crawford
    Duke Comprehensive Cancer Center, Duke University, Durham, NC, USA
    J Natl Compr Canc Netw 3:540-55. 2005
  64. ncbi request reprint G-CSF as prophylaxis of febrile neutropenia in SCLC
    Jared R Adams
    The Chicago Veterans Administration Healthcare System, Lakeside Division, Lakeside VA, 400 E Ontario Ave, IL 60611, USA
    Expert Opin Pharmacother 3:1273-81. 2002
    ..We reviewed 13 health services research studies that addressed CSF use as supportive care for SCLC...
  65. ncbi request reprint Myeloid growth factors. Clinical practice guidelines in oncology
    Jeffrey Crawford
    J Natl Compr Canc Netw 5:188-202. 2007
  66. ncbi request reprint Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials
    Otavio A C Clark
    Hospital Celso Pierro PUC Campinas, Sao Paulo, Brazil
    J Clin Oncol 23:4198-214. 2005
    ..This Cochrane Collaboration review was undertaken to further evaluate the safety and efficacy of the CSFs in patients with FN...
  67. ncbi request reprint Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer
    John Hornberger
    The SPHERE Institute Acumen, LLC, Burlingame, CA 94010, USA
    Am J Manag Care 11:313-24. 2005
    ....
  68. doi request reprint Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer
    Chaitanya R Acharya
    Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina 27708, USA
    JAMA 299:1574-87. 2008
    ..Gene expression profiling may be useful for prognostic and therapeutic strategies in breast carcinoma...
  69. ncbi request reprint Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registry
    Debra Wolff
    J Support Oncol 3:24-5. 2005
  70. ncbi request reprint Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice
    Jeffrey Crawford
    Duke University, Durham, North Carolina, USA
    J Natl Compr Canc Netw 6:109-18. 2008
    ..Despite frequent planned reductions from standard RDI, the incidence of FN remains high in community oncology practice in the United States. Improved methods of pretreatment assessment of patient risk factors for neutropenia are needed...
  71. ncbi request reprint Introduction. Neutropenia risk models in oncology
    Gary H Lyman
    Oncology (Williston Park) 17:5-7. 2003
  72. ncbi request reprint Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy
    Leon E Cosler
    Albany College of Pharmacy, Albany, NY, USA
    Value Health 8:47-52. 2005
    ..We sought to determine these costs, both overall and relative to those of traditional management, and the optimal role of prophylactic colony-stimulating factor (CSF) in patients at greatest risk for FN...
  73. ncbi request reprint Hemopoiesis and aging
    Lodovico Balducci
    Senior Adult Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Cancer Treat Res 124:109-34. 2005
  74. ncbi request reprint Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries
    Jared R Adams
    Department of Veterans Affairs, the MidWest Center for Health Services and Policy Research and the Veterans Affairs Chicago Healthcare System Lakeside Division, Chicago, Illinois, USA
    Am J Med 116:28-34. 2004
    ..To assess physician use of erythropoietin in cancer patients before publication of the American Society of Clinical Oncology/American Society of Hematology guidelines...
  75. ncbi request reprint Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management
    Jeffrey Crawford
    Divisions of Oncology and Hematology, Duke University Medical Center, PO Box 25178 Morris Building, Durham, NC 27710 0001, USA
    Cancer 100:228-37. 2004
    ..Research in quantifying the risk of neutropenic complications may make it possible in the near future to target patients at greater risk with appropriate preventive strategies, thereby maximizing the benefits and minimizing the costs...
  76. ncbi request reprint Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy
    Leon E Cosler
    Department of Humanities and Social Sciences, Albany College of Pharmacy, New York 12208, USA
    Pharmacotherapy 24:488-94. 2004
    ..Costs were included in an existing cost-minimization model, and their effect on the risk threshold at which the prophylactic use of CSF becomes cost saving was determined...